About Rgenta
Rgenta is a Healthcare company based in Cambridge (United States) founded in 2018 by Zhiping Weng, Simon Xi, and Travis Wager. RNA-based therapeutics are developed for multiple disorders. Rgenta has raised $90 million across 5 funding rounds from investors including Astrazeneca, HHS and Delos Capital. The company has 11 employees. Its chief executive, as recorded, is Simon Xi. Rgenta offers products and services including RNA-Targeting Medicines and Discovery Platform. Its focus areas include Life Sciences, Clinical Genomics, Sequencing Based and Genetic Testing. Its legal entity is Rgenta Therapeutics, Inc.,. Its competitors include Moderna, BridgeBio and BeiGene; 3 of its 3 listed competitors have raised funding.
Company details
Founded in 2018 and based in Cambridge, United States, Rgenta operates in the biotechnology sector. RNA-based therapeutics are developed to address various disorders through compound libraries designed to identify and modulate RNA target sites, especially those involving regulatory proteins. A data-driven platform for mRNA target identification is utilized, incorporating cell type-specific regulation to forecast outcomes of target modulation.
- Headquarters Cambridge, United States
- Employees 11
- Founders Zhiping Weng, Simon Xi, Travis Wager
- SectorsHealthcare
- Email••••••••
- Website rgentatx.com
- Social LinkedIn
- Legal Name Rgenta Therapeutics, Inc.,
- Total Equity Funding$90M (USD)
in 5 rounds
- InvestorsAstrazeneca
& 11 more
- Employee Count11
Products & Services of Rgenta
Rgenta offers a comprehensive portfolio of products and services, including RNA-Targeting Medicines and Discovery Platform.
Oral small-molecule drugs for treating oncology and neurological disorders.
Platform for developing RNA-targeted small molecule therapies.
Funding Insights of Rgenta
Rgenta has successfully raised a total of $90M across 5 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $90M
- Total Rounds 5
- First Round $20M
(Feb 2020)
- Investors Count 12
All 5 funding rounds of Rgenta with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2025 | Series A | – | – | ||
| Nov 2022 | $52M | Series A | – | Astrazeneca | |
| May 2021 | $18M | Seed | – | – | – |
| Sep 2020 | $400,034 | Grant | – | – | |
| Feb 2020 | $20M | Seed | – | Boehringer Ingelheim Venture Fund, Matrix Partners China | – |
12 investors in total: 12 institutional.
Investors in Rgenta
Rgenta has secured backing from 12 investors, including institutional and venture fund investors. Prominent investors backing the company include Astrazeneca, HHS and Delos Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Delos Capital is engaged in private equity and financial advisory services. | deloscap.com | New York City, United States | ||
Early-stage ventures are funded by the investment firm. | matrix.vc | San Francisco, United States | ||
Venture capital and private equity firm | vivocapital.com | Palo Alto, United States | ||
Kaitai Capital is engaged in innovation investment management services. | kaitaicapital.com | Hangzhou, China | ||
Healthcare investments are targeted by Boehringer Ingelheim Venture Fund. | boehringer-ingelheim-venture.com | |||
Tech startups are invested in by this venture capital firm. | kipvc.cn | Singapore, Singapore | ||
Chinese startups are funded and incubated by Legend Star. | legendstar.com.cn | Beijing, China | ||
Multiple sectors are invested in by this venture capital firm. | matrixpartners.com.cn | Chaoyang, China | ||
| eqtgroup.com | ||||
Pharmaceutical and biologics products are developed and distributed worldwide. | 1913 | astrazeneca.com | Cambridge, United Kingdom |
Investor details for Rgenta
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Rgenta
3 people are tracked at Rgenta (3 in leadership); the tracked headcount is 11.
| Name | Role | Group |
|---|---|---|
Zhiping Weng | Co-Founder | Leadership |
Simon Xi | Co-Founder & CEO | Leadership |
Travis Wager | Co-Founder & CSO | Leadership |
Complete people profiles for Rgenta
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Rgenta
3 dated milestones of Rgenta across 7 years, from founding to its latest funding, stage changes and deals.
- Founded Rgenta is founded.
- Funding First funding round of $20.0M.
- Funding Latest funding round, Series A,.
Competitors of Rgenta
Rgenta has 3 listed competitors in our database, 3 of them funded. They include Moderna, BridgeBio and BeiGene.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | Therapeutics for genetic diseases are developed through targeted interventions. | ||
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. |
Detailed competitors of Rgenta
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Rgenta
The website of Rgenta (rgentatx.com) receives about 1.8K visits a month.
- Monthly visits1.8K
▲ 26% vs previous month
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Rgenta (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Rgenta
Complete news archive for Rgenta
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Rgenta
Rgenta was founded in 2018 and raised its 1st funding round 2 years after it was founded.
Rgenta is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Simon Xi is the CEO of Rgenta, as recorded in our data. They have also founded this company.
Rgenta is a funded company, having raised a total of $90M across 5 funding rounds to date. The company's 1st funding round was a Seed of $20M, raised on Feb 2020.
Rgenta has 11 employees.
Founded in 2018 and based in Cambridge, United States, Rgenta operates in the biotechnology sector. RNA-based therapeutics are developed to address various disorders through compound libraries designed to identify and modulate RNA target sites, especially those involving regulatory proteins. A data-driven platform for mRNA target identification is utilized, incorporating cell type-specific regulation to forecast outcomes of target modulation.
Rgenta offers RNA-Targeting Medicines and Discovery Platform.
Rgenta has 12 investors. Key investors include Astrazeneca, HHS, Delos Capital, Matrix, and Lilly Asia Ventures.
Rgenta operates through Rgenta Therapeutics, Inc.,.